ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.

PLoS One · 2018 · PMC6104973 · PMID 30133535

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Interestingly, the combination treatment of ALX148 and anti-PD-1 showed a trend towards reduced CD4 + Treg infiltrates and decreased proliferative potential as evidenced by reduced Ki67 staining ( Fig 8A and 8B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.